Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06570941 · ClinicalTrials.gov registry record · Phase 1
Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome
A Phase 1 study of Restless Legs Syndrome, sponsored by Synthonics.
- Active
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06570941: Active Phase 1 study of Restless Legs Syndrome, sponsored by Synthonics.
NCT06570941 is a Phase 1 study of Restless Legs Syndrome that is active but no longer recruiting, run by Synthonics. The registered enrollment target is 10 participants, below the 96-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06570941, a Phase 1 study of Restless Legs Syndrome, is active but no longer recruiting, sponsored by Synthonics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this open label clinical trial is to reduce the effects of restless leg syndrome. The main it questions it aims to answer are: 1. Reduce or eliminate the symptoms of restless leg syndrome. 2. Improve the quality of life of participants with restless leg syndrome. Participants will be asked to apply the topical cream to the affected area 30 to 45 minutes before bedtime for 14 consecutive days.
Conditions Studied
Interventions
- DRUG Chylobinoid Topical Cream
Study Locations (1)
Florida
- Synthonics - Sarasota
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 1 |
What the registry record for NCT06570941 still lists
NCT06570941 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 96-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Restless Legs Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Chylobinoid Topical Cream is the first listed.
NCT06570941 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06570941 about?
NCT06570941 is a clinical study titled "Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome". The goal of this open label clinical trial is to reduce the effects of restless leg syndrome. The main it questions it aims to answer are: 1. Reduce or eliminate the symptoms of restless leg syndrome. 2. Improve the quality of life of participants with restless leg syndrome. Participants will be a...
What is the current status of trial NCT06570941?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-03-01. Estimated completion is 2024-10-31.
What conditions does trial NCT06570941 study?
This clinical trial studies the following conditions: Restless Legs Syndrome.
What interventions are being tested in trial NCT06570941?
The interventions under investigation include: Chylobinoid Topical Cream (DRUG).
Who is sponsoring clinical trial NCT06570941?
This trial is sponsored by Synthonics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06570941 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Restless Legs Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06570941's enrollment target sits among peer trials
10 15th of 14 the lowest of 14 other Restless Legs Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Restless Legs Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole
COMPLETED · Phase 1
-
A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers
COMPLETED · Phase 1
-
Blood Changes After Exercise in Restless Legs Syndrome
RECRUITING · NA
-
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
ACTIVE NOT RECRUITING · Phase 4
-
Response to an Investigational Device in Patients With Restless Legs Syndrome
ACTIVE NOT RECRUITING · NA
-
A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI